Academic Journal
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
| Τίτλος: | Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer |
|---|---|
| Συγγραφείς: | Vergote, I., González-Martín, A., Fujiwara, K., Kalbacher, E., Bagaméri, A., Ghamande, S., Lee, Jung-Yun, Banerjee, Susana, Maluf, F.C., Lorusso, D., Yonemori, K., Nieuwenhuysen, E. Van, Manso, L., Woelber, L., Westermann, A., Covens, A., Hasegawa, K., Kim, B.G., Raimondo, M., Bjurberg, M., Cruz, F.M., Angelergues, A., Cibula, D., Barraclough, L., Oaknin, A., Gennigens, C., Nicacio, L., Teng, M.S.L., Whalley, E., Ottevanger, P.B., Soumaoro, I., Slomovitz, B.M. |
| Συνεισφορές: | Genmab, Pfizer |
| Πηγή: | The New England Journal of Medicine, 391, 1, pp. 44-55 |
| Στοιχεία εκδότη: | Massachusetts Medical Society, 2024. |
| Έτος έκδοσης: | 2024 |
| Θεματικοί όροι: | Adult, Oncologie, Uterine Cervical Neoplasms, Antibodies, Monoclonal/therapeutic use, Kaplan-Meier Estimate, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/administration & dosage, Sciences de la santé humaine, Uterine Cervical Neoplasms/mortality, Antineoplastic Combined Chemotherapy Protocols, Humans, Uterine Cervical Neoplasms/drug therapy, Human health sciences, Medical Oncology - Radboud University Medical Center, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antibodies, Monoclonal, Middle Aged, Survival Analysis, Progression-Free Survival, Neoplasm Recurrence, Local/drug therapy, Oncology, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local, Oligopeptides |
| Περιγραφή: | Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival.A total of 502 patients underwent randomization (253 were assigned to the tisotumab vedotin group and 249 to the chemotherapy group); the groups were similar with respect to demographic and disease characteristics. The median overall survival was significantly longer in the tisotumab vedotin group than in the chemotherapy group (11.5 months [95% confidence interval {CI}, 9.8 to 14.9] vs. 9.5 months [95% CI, 7.9 to 10.7]), results that represented a 30% lower risk of death with tisotumab vedotin than with chemotherapy (hazard ratio, 0.70; 95% CI, 0.54 to 0.89; two-sided P = 0.004). The median progression-free survival was 4.2 months (95% CI, 4.0 to 4.4) with tisotumab vedotin and 2.9 months (95% CI, 2.6 to 3.1) with chemotherapy (hazard ratio, 0.67; 95% CI, 0.54 to 0.82; two-sided P |
| Τύπος εγγράφου: | Article |
| Γλώσσα: | English |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejmoa2313811 |
| Σύνδεσμος πρόσβασης: | https://pubmed.ncbi.nlm.nih.gov/38959480 https://hdl.handle.net/2066/310949 https://repository.ubn.ru.nl//bitstream/handle/2066/310949/310949.pdf |
| Rights: | URL: http://www.nejmgroup.org/legal/terms-of-use.htm |
| Αριθμός Καταχώρησης: | edsair.doi.dedup.....11e6c1d7da7fca4bd4aedec20de6feef |
| Βάση Δεδομένων: | OpenAIRE |
| ISSN: | 15334406 00284793 |
|---|---|
| DOI: | 10.1056/nejmoa2313811 |